8-K: Acrivon Reports Positive Clinical Data, Extends Cash Runway

Acrivon Therapeutics announces positive Phase 2b clinical data for ACR-368 in endometrial cancer, initial Phase 1 data for ACR-2316, nominated a new development candidate ACR-6840, and reported preliminary cash of $119 million, extending its operational runway into Q2 2027.

Summary

• Preliminary unaudited cash, cash equivalents, and investments were approximately $119 million as of December 31, 2025, expected to fund operations into the second quarter of 2027.
• ACR-368 Phase 2b registrational-intent trial (monotherapy BM+ subjects) showed an overall response rate (ORR) of 39%, increasing to 44% in subjects with 2 prior lines of therapy.
• In serous endometrial cancer (EC) subjects with 2 prior lines of therapy, the confirmed ORR (cORR) was 52% (N=23) across both BM+ and BMsubjects, and 67% in BM+ subjects (N=12).
• Arm 3 of the ACR-368 trial will now focus exclusively on serous EC subjects with 2 prior lines of therapy, without requiring a tumor biopsy, with initial EU enrollment expected in Q1 2026 and completion anticipated in Q4 2026.
• A proposed protocol design for a planned Phase 3 confirmatory study evaluating ACR-368 in combination with an anti-PD-1 agent in frontline advanced/recurrent pMMR EC subjects was submitted to the FDA on November 12, 2025.
• Initial clinical data from the ACR-2316 Phase 1 monotherapy dose-escalation study (N=33) established two weekly oral dosing regimens (160 mg QD 3d on/4d off and 240 mg QD 2d on/5d off) with a favorable tolerability profile.
• ACR-2316 demonstrated tumor shrinkage in 9 out of 20 evaluable patients at dose levels 120 mg and above, including a confirmed partial response (PR) in EC and unconfirmed PRs in SCLC and sqNSCLC, tumor types not previously sensitive to other WEE1 or PKMYT1 inhibitors.
• ACR-6840, a potential first-in-class CDK11 inhibitor, was nominated as the next development candidate from the AP3-driven cell cycle program, with IND submission anticipated in Q4 2026.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for both lead candidates, ACR-368 and ACR-2316, with promising response rates in difficult-to-treat cancers and a favorable tolerability profile. The nomination of a new development candidate, ACR-6840, demonstrates pipeline growth, and the extended cash runway provides financial stability.

Positives

• A strong preliminary cash position of approximately $119 million as of December 31, 2025, is expected to fund operations into the second quarter of 2027.
• Positive interim Phase 2b data for ACR-368 in endometrial cancer, particularly a cORR of 52% (overall) and 67% (BM+) in serous EC subjects with 2 prior lines of therapy, indicates a highly compelling clinical profile.
• Expansion of ACR-368 Arm 3 into the EU with over 20 sites across four major countries is expected to accelerate enrollment and potentially validate clinical significance with as few as 40 subjects.
• Submission of a Phase 3 confirmatory study protocol for ACR-368 to the FDA signals progression towards later-stage development and potential market entry.
• ACR-2316 demonstrated a favorable tolerability profile and observed tumor shrinkage in Phase 1, including confirmed and unconfirmed partial responses in heavily pretreated subjects with EC, SCLC, and sqNSCLC.
• ACR-2316 showed activity in SCLC and sqNSCLC, two tumor types not previously sensitive to other WEE1 or PKMYT1 inhibitors currently in development, highlighting the potential differentiation and value of the AP3 platform.
• Nomination of ACR-6840 as a new, potential first-in-class CDK11 inhibitor demonstrates pipeline growth and continued utility of the proprietary AP3 platform for rational drug design.

Negatives

• The preliminary financial information regarding cash, cash equivalents, and investments is unaudited and subject to change, and actual amounts may differ materially.
• No further feedback has been received from the FDA on the proposed Phase 3 protocol design for ACR-368, which could introduce uncertainty regarding the timeline.
• One subject with SCLC who achieved an unconfirmed PR showed progression of liver metastases in non-target lesions after the date of the EDC extract, indicating potential limitations or disease heterogeneity.

Risks

• Preliminary financial information is unaudited and subject to completion of financial closing procedures, and actual amounts may differ materially from the preliminary estimate.
• Forward-looking statements involve substantial risks and uncertainties, and actual results could differ materially from expectations.
• Factors that could cause actual results to differ are described more fully in the 'Risk Factors' section of Acrivon's reports filed with the Securities and Exchange Commission.

Future Outlook

Acrivon anticipates initiating EU enrollment for ACR-368 Arm 3 in Q1 2026, providing further ACR-368 data updates and achieving Phase 3 readiness by mid-2026, and completing ACR-368 Arm 3 enrollment by Q4 2026. The company also expects to report additional ACR-2316 Phase 1 data and transition to dose expansion in 1H 2026, submit an IND for ACR-6840 in Q4 2026, and initiate new internal AP3 programs in 2H 2026. Preliminary cash of $119 million is expected to fund operations into Q2 2027.

Management Comments

• "We are pleased with tangible progress accelerating across multiple high-value opportunities." Peter Blume-Jensen, M.D., Ph.D., CEO, President, and Co-founder.
• "We are particularly excited by the observation from our ongoing ACR-368 Phase 2 trial that subjects with serous endometrial cancer with up to two prior lines of therapy are showing over 50% confirmed response rate." Peter Blume-Jensen.
• "This provides an attractive opportunity for rapid Arm 3 enrollment without the need for a pretreatment biopsy, both in the US and more than 20 newly selected sites in major EU countries, with anticipated enrollment completion in 2026." Peter Blume-Jensen.
• "Given the high response rate we have observed, and that we intend to give all patients ULDG as a sensitizer for ACR-368, we believe the data from our ongoing study provide for a highly compelling clinical profile in this high unmet need patient population." Peter Blume-Jensen.
• "About a third of all secondand third-line endometrial cancer cases are of serous subtype and represent a challenging patient population." Mansoor Raza Mirza, M.D., Chief Medical Officer.
• "Moreover, incorporating feedback from a Type B meeting in June 2025, we have recently submitted our Phase 3 confirmatory study protocol to the FDA for ACR-368 in combination with anti-PD-1 therapy in frontline endometrial cancer patients, building on the strong synergy observed preclinically between these two agents." Mansoor Raza Mirza.
• "We are also very encouraged by the initial clinical data for ACR-2316, including the favorable tolerability profile and observed tumor shrinkage across multiple AP3-prioritized tumor types, including partial responses in heavily pretreated subjects with endometrial cancer, SCLC and squamous NSCLC." Peter Blume-Jensen.
• "Finally, we continue to demonstrate the value of our AP3 platform with the nomination from our cell cycle program of ACR-6840, a potential first-in-class CDK11 inhibitor development candidate, with IND submission expected in the fourth quarter of 2026." Peter Blume-Jensen.
• "We believe these achievements represent transformative progress toward delivering meaningful new precision medicine treatment options for cancer patients with high unmet need." Peter Blume-Jensen.

Industry Context

Acrivon Therapeutics is advancing precision medicines in the highly competitive oncology sector. Its proprietary Generative Phosphoproteomics AP3 platform aims to differentiate by interpreting and quantifying drug-regulated pathway activity, enabling rational drug design and predictive clinical development. The company's focus on high unmet need populations, such as serous endometrial cancer and difficult-to-treat SCLC/sqNSCLC, with novel inhibitors (CHK1/2, WEE1/PKMYT1, CDK11) positions it within the innovative segment of cancer therapeutics. The strategic expansion of clinical trials into the EU is a common approach for accelerating patient enrollment in global studies.

Comparison to Industry Standards

• ACR-2316 demonstrated clinical activity, including tumor shrinkage and partial responses, in Small Cell Lung Cancer (SCLC) and squamous Non-Small Cell Lung Cancer (sqNSCLC), two tumor types that "have not shown sensitivity to other clinical WEE1 or PKMYT1 inhibitors currently in development," suggesting a potential differentiation from competitors in this class.
• The confirmed overall response rate (cORR) of 52% (overall) and 67% (BM+) observed for ACR-368 in serous endometrial cancer subjects with 2 prior lines of therapy is described by management as a "highly compelling clinical profile in this high unmet need patient population," implying favorable efficacy compared to existing treatment options for this challenging subtype.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, pipeline progression, and extended cash runway, potentially increasing company valuation and future revenue prospects.
• Patients: Potential for new, effective precision medicine treatment options for high unmet need cancer populations, particularly those with serous endometrial cancer, SCLC, and sqNSCLC.
• Employees: Continued progress and pipeline expansion suggest job stability and growth opportunities within the company.
• Regulatory Authorities: Ongoing engagement with the FDA (Type B meeting, Phase 3 protocol submission) indicates adherence to regulatory processes.

Next Steps

• Initiate enrollment for Arm 3 of the ACR-368 Phase 2 trial in EU in Q1 2026.
• Provide additional update on Arm 1 and initial clinical data from Arm 3 of the ACR-368 Phase 2 trial in mid-2026.
• Achieve readiness for Phase 3 confirmatory trial for ACR-368 in combination with PD-1 therapy in mid-2026.
• Complete enrollment (planned N = 90 subjects) in the biopsy-independent Phase 2 Arm 3 trial for ACR-368 combined with ULDG as a sensitizer in Q4 2026.
• Report additional ACR-2316 Phase 1 clinical data in weekly and bi-weekly dosing regimens and transition into dose expansion in select tumor types in 1H 2026.
• Submit IND to FDA for ACR-6840 in Q4 2026.
• Initiate additional internal programs utilizing the AP3 platform in 2H 2026.

Key Dates

Recommendation

The filing details significant positive clinical advancements across Acrivon's lead programs, ACR-368 and ACR-2316, demonstrating compelling response rates and favorable tolerability in challenging cancer indications. The strategic expansion of ACR-368's Phase 2b trial into the EU and the submission of a Phase 3 protocol to the FDA signal accelerated development towards potential market entry. Furthermore, the nomination of ACR-6840 validates the company's proprietary AP3 platform and strengthens its long-term pipeline. With a preliminary cash runway extending into Q2 2027, the company appears well-capitalized to execute its near-term milestones. These factors collectively suggest a strong growth trajectory and significant upside potential for investors.

Keywords

Acrivon Therapeutics, ACRV, Endometrial Cancer, CHK1/CHK2 Inhibitor, ACR-368, WEE1/PKMYT1 Inhibitor, ACR-2316, CDK11 Inhibitor, ACR-6840, AP3 Platform, Oncology, Clinical Trials, Phase 2b, Phase 1, IND Submission, Biotechnology, Precision Medicine, Uterine Serous Carcinoma, Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Cash Runway